服务平台拥有丰富的技术服务经验，一流的仪器设备，先进的检测手段和严格的质量控制体系，力求为全球药物研发机构提供优质高效的技术服务
产品介绍 Human MLK4, also known as Mixed Lineage Kinase 4, and KIAA1804, GenBank Accession No. NM_032435, a.a. 1-557, with N-terminal GST-tag, MW = 61 kDa, expressed in Sf9 cells via a baculovirus expression system.
询价产品介绍 Human MLK3, also known as Mixed Lineage Kinase 3, Mitogen-activated protein kinase kinase kinase 11, MAP3K11, PTK1, SPRK, and MGC17114, GenBank Accession No. NM_002419, a.a. 1-488, with N-terminal GST-tag, MW = 83 kDa, expressed in Sf9 cells via a baculovirus expression system.
询价产品介绍 Human MLK2, also known as Mixed Lineage Kinase 2, Mitogen-activated protein kinase kinase kinase 10, MAP3K10, and MST, GenBank Accession No. NM_002446, a.a. 1-446, with N-terminal GST-tag, MW = 76 kDa, expressed in Sf9 cells via a baculovirus expression system.
询价产品介绍 Human MLK1, also known as Mixed Lineage Kinase 1, Mitogen-activated protein kinase kinase kinase 9, MAP3K9, MEKK9, and PRKE1, GenBank Accession No. NM_033141, a.a. 1-433, with N-terminal GST-tag, MW = 77 kDa, expressed in Sf9 cells via a baculovirus expression system.
询价背景介绍 LRRK2 or leucine-rich repeat kinase is a protein with an ankryin repeat region, a leucine-rich repeat (LRR) domain, a kinase domain, a DFG-like motif, a RAS domain, a GTPase domain, a MLK-like domain, and a WD40 domain. Mutations in LRRK2 are the most frequent known cause of autosomal dominant and idiopathic Parkinson's disease with prevalent mutations being found within the GTPase and kinase domains (1). LRRK2 cooperates with MET to promote efficient tumor cell growth and survival in various cancers. Down-regulation of LRRK2 in cultured tumor cells compromises MET activation and selectively reduces downstream MET signaling to mTOR and STAT3 (2). 产品介绍 Human LRRK2, also known as PARK8, RIPK7, and ROCO2, GenBank Accession No. NM_198578, amino acids 968-end, with an N-terminal GST-tag, expressed in an SF9 cell expression system. MW = 210 kDa.
询价背景介绍 LRRK2 or leucine-rich repeat kinase is a protein with an ankryin repeat region, a leucine-rich repeat (LRR) domain, a kinase domain, a DFG-like motif, a RAS domain, a GTPase domain, a MLK-like domain, and a WD40 domain. Mutations in LRRK2 are the most frequent known cause of autosomal dominant and idiopathic Parkinson's disease with prevalent mutations being found within the GTPase and kinase domains (1). LRRK2 cooperates with MET to promote efficient tumor cell growth and survival in various cancers. Down-regulation of LRRK2 in cultured tumor cells compromises MET activation and selectively reduces downstream MET signaling to mTOR and STAT3 (2). 产品介绍 Human LRRK2 protein with a Y1699G mutation, also known as PARK8, RIPK7, and ROCO2, GenBank Accession No. NM_198578, amino acids 968-end, with an N-terminal GST-tag, expressed in an SF9 cell expression system. MW = 210 kDa.
询价背景介绍 LRRK2 or leucine-rich repeat kinase is a protein with an ankryin repeat region, a leucine-rich repeat (LRR) domain, a kinase domain, a DFG-like motif, a RAS domain, a GTPase domain, a MLK-like domain, and a WD40 domain. Mutations in LRRK2 are the most frequent known cause of autosomal dominant and idiopathic Parkinson's disease with prevalent mutations being found within the GTPase and kinase domains (1). LRRK2 cooperates with MET to promote efficient tumor cell growth and survival in various cancers. Down-regulation of LRRK2 in cultured tumor cells compromises MET activation and selectively reduces downstream MET signaling to mTOR and STAT3 (2). 产品介绍 Human LRRK2 protein with a Y1699C mutation, also known as PARK8, RIPK7, and ROCO2, GenBank Accession No. NM_198578, amino acids 968-end, with an N-terminal GST-tag, expressed in an SF9cell expression system. MW = 210 kDa.
询价背景介绍 LRRK2 or leucine-rich repeat kinase is a protein with an ankryin repeat region, a leucine-rich repeat (LRR) domain, a kinase domain, a DFG-like motif, a RAS domain, a GTPase domain, a MLK-like domain, and a WD40 domain. Mutations in LRRK2 are the most frequent known cause of autosomal dominant and idiopathic Parkinson's disease with prevalent mutations being found within the GTPase and kinase domains (1). LRRK2 cooperates with MET to promote efficient tumor cell growth and survival in various cancers. Down-regulation of LRRK2 in cultured tumor cells compromises MET activation and selectively reduces downstream MET signaling to mTOR and STAT3 (2). 产品介绍 Human LRRK2 protein with a R1441H mutation, also known as PARK8, RIPK7, and ROCO2, GenBank Accession No. NM_198578, amino acids 968-end, with an N-terminal GST-tag, expressed in an SF9cell expression system. MW = 210 kDa.
询价背景介绍 LRRK2 or leucine-rich repeat kinase is a protein with an ankryin repeat region, a leucine-rich repeat (LRR) domain, a kinase domain, a DFG-like motif, a RAS domain, a GTPase domain, a MLK-like domain, and a WD40 domain. Mutations in LRRK2 are the most frequent known cause of autosomal dominant and idiopathic Parkinson's disease with prevalent mutations being found within the GTPase and kinase domains (1). LRRK2 cooperates with MET to promote efficient tumor cell growth and survival in various cancers. Down-regulation of LRRK2 in cultured tumor cells compromises MET activation and selectively reduces downstream MET signaling to mTOR and STAT3 (2). 产品介绍 Human LRRK2 protein with a R1441G mutation, also known as PARK8, RIPK7, and ROCO2, GenBank Accession No. NM_198578, amino acids 968-end, with an N-terminal GST-tag, expressed in an SF9cell expression system. MW = 210 kDa.
询价
